These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26496175)

  • 1. Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.
    Lim SM; Jeong Y; Lee S; Im H; Tae HS; Kim BG; Park HD; Park J; Hong S
    J Med Chem; 2015 Nov; 58(21):8491-502. PubMed ID: 26496175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.
    Ferch U; Kloo B; Gewies A; Pfänder V; Düwel M; Peschel C; Krappmann D; Ruland J
    J Exp Med; 2009 Oct; 206(11):2313-20. PubMed ID: 19841089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.
    Hailfinger S; Lenz G; Ngo V; Posvitz-Fejfar A; Rebeaud F; Guzzardi M; Penas EM; Dierlamm J; Chan WC; Staudt LM; Thome M
    Proc Natl Acad Sci U S A; 2009 Nov; 106(47):19946-51. PubMed ID: 19897720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.
    Fontan L; Yang C; Kabaleeswaran V; Volpon L; Osborne MJ; Beltran E; Garcia M; Cerchietti L; Shaknovich R; Yang SN; Fang F; Gascoyne RD; Martinez-Climent JA; Glickman JF; Borden K; Wu H; Melnick A
    Cancer Cell; 2012 Dec; 22(6):812-24. PubMed ID: 23238016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.
    Nagel D; Spranger S; Vincendeau M; Grau M; Raffegerst S; Kloo B; Hlahla D; Neuenschwander M; Peter von Kries J; Hadian K; Dörken B; Lenz P; Lenz G; Schendel DJ; Krappmann D
    Cancer Cell; 2012 Dec; 22(6):825-37. PubMed ID: 23238017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.
    Liang X; Sun C; Li C; Yu H; Wei X; Liu X; Bao W; Shi Y; Sun X; Khamrakulov M; Yang C; Liu H
    J Med Chem; 2021 Jul; 64(13):9217-9237. PubMed ID: 34181850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL.
    Fontan L; Goldstein R; Casalena G; Durant M; Teater MR; Wilson J; Phillip J; Xia M; Shah S; Us I; Shinglot H; Singh A; Inghirami G; Melnick A
    Blood; 2021 Feb; 137(6):788-800. PubMed ID: 32785655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
    Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
    Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.
    Seshadri MR; Melnick AM
    Leuk Lymphoma; 2022 Apr; 63(4):789-798. PubMed ID: 34783281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of new Malt1 inhibitors and probes.
    Xin BT; Schimmack G; Du Y; Florea BI; van der Marel GA; Driessen C; Krappmann D; Overkleeft HS
    Bioorg Med Chem; 2016 Aug; 24(15):3312-29. PubMed ID: 27085674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-
    Liang X; Yu H; Liang R; Feng Z; Saidahmatov A; Sun C; Ren H; Wei X; Zhao J; Yang C; Liu H
    J Med Chem; 2024 Feb; 67(4):2884-2906. PubMed ID: 38349664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autocleavage of the paracaspase MALT1 at Arg-781 attenuates NF-κB signaling and regulates the growth of activated B-cell like diffuse large B-cell lymphoma cells.
    Wu CH; Yang YH; Chen MR; Tsai CH; Cheng AL; Doong SL
    PLoS One; 2018; 13(6):e0199779. PubMed ID: 29953499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation.
    Knies N; Alankus B; Weilemann A; Tzankov A; Brunner K; Ruff T; Kremer M; Keller UB; Lenz G; Ruland J
    Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7230-8. PubMed ID: 26668357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth.
    Fontán L; Qiao Q; Hatcher JM; Casalena G; Us I; Teater M; Durant M; Du G; Xia M; Bilchuk N; Chennamadhavuni S; Palladino G; Inghirami G; Philippar U; Wu H; Scott DA; Gray NS; Melnick A
    J Clin Invest; 2018 Oct; 128(10):4397-4412. PubMed ID: 30024860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The protease activity of the paracaspase MALT1 is controlled by monoubiquitination.
    Pelzer C; Cabalzar K; Wolf A; Gonzalez M; Lenz G; Thome M
    Nat Immunol; 2013 Apr; 14(4):337-45. PubMed ID: 23416615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas.
    Minderman M; Lantermans HC; Grüneberg LJ; Cillessen SAGM; Bende RJ; van Noesel CJM; Kersten MJ; Pals ST; Spaargaren M
    Blood Cancer J; 2023 Mar; 13(1):37. PubMed ID: 36922488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attacking MALT1 for ABC-DLBCL therapy.
    Krappmann D
    Oncotarget; 2012 Dec; 3(12):1489-90. PubMed ID: 23455231
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.
    Fontán L; Melnick A
    Clin Cancer Res; 2013 Dec; 19(24):6662-8. PubMed ID: 24004675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-aryl-piperidine-4-carboxamides as a novel class of potent inhibitors of MALT1 proteolytic activity.
    Schlapbach A; Revesz L; Pissot Soldermann C; Zoller T; Régnier CH; Bornancin F; Radimerski T; Blank J; Schuffenhauer A; Renatus M; Erbel P; Melkko S; Heng R; Simic O; Endres R; Wartmann M; Quancard J
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2153-2158. PubMed ID: 29759726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
    Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
    Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.